Shadreck M. Mareya

1.3k total citations · 1 hit paper
25 papers, 913 citations indexed

About

Shadreck M. Mareya is a scholar working on Gastroenterology, Surgery and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Shadreck M. Mareya has authored 25 papers receiving a total of 913 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Gastroenterology, 14 papers in Surgery and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Shadreck M. Mareya's work include Gastrointestinal motility and disorders (20 papers), Gastroesophageal reflux and treatments (10 papers) and Intestinal and Peritoneal Adhesions (6 papers). Shadreck M. Mareya is often cited by papers focused on Gastrointestinal motility and disorders (20 papers), Gastroesophageal reflux and treatments (10 papers) and Intestinal and Peritoneal Adhesions (6 papers). Shadreck M. Mareya collaborates with scholars based in United States, Netherlands and Qatar. Shadreck M. Mareya's co-authors include William P. Forbes, Audrey L. Shaw, William D. Chey, Enoch Bortey, Anthony Lembo, Salam Zakko, Mark Pimentel, Jing Yu, Yehuda Ringel and Peter Lichtlen and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

Shadreck M. Mareya

22 papers receiving 875 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

2011 720 citations Mark Pimentel, Anthony Lembo et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shadreck M. Mareya United States	8	763	380	203	192	155	25	913
P.-O. Stotzer Sweden	8	560 0.7×	336 0.9×	163 0.8×	94 0.5×	89 0.6×	11	730
Eamonn Martin Quigley United States	12	561 0.7×	394 1.0×	157 0.8×	73 0.4×	75 0.5×	39	821
David Andrae United States	10	505 0.7×	254 0.7×	167 0.8×	52 0.3×	69 0.4×	35	693
Baha Moshiree United States	9	524 0.7×	238 0.6×	146 0.7×	83 0.4×	81 0.5×	26	706
I. Fumagalli Switzerland	11	788 1.0×	549 1.4×	197 1.0×	100 0.5×	89 0.6×	24	1.1k
Vicente Garrigues Spain	22	868 1.1×	810 2.1×	187 0.9×	132 0.7×	57 0.4×	66	1.3k
JO Hunter United Kingdom	7	295 0.4×	225 0.6×	98 0.5×	106 0.6×	73 0.5×	20	540
Chamara Basnayake Australia	12	225 0.3×	150 0.4×	64 0.3×	119 0.6×	55 0.4×	42	548
M. A. Benninga Netherlands	17	471 0.6×	413 1.1×	57 0.3×	31 0.2×	209 1.3×	57	847
Raymond M. Panas United States	9	600 0.8×	373 1.0×	156 0.8×	40 0.2×	90 0.6×	27	680

Countries citing papers authored by Shadreck M. Mareya

Since Specialization

Citations

This map shows the geographic impact of Shadreck M. Mareya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shadreck M. Mareya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shadreck M. Mareya more than expected).

Fields of papers citing papers by Shadreck M. Mareya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shadreck M. Mareya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shadreck M. Mareya. The network helps show where Shadreck M. Mareya may publish in the future.

Co-authorship network of co-authors of Shadreck M. Mareya

This figure shows the co-authorship network connecting the top 25 collaborators of Shadreck M. Mareya. A scholar is included among the top collaborators of Shadreck M. Mareya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shadreck M. Mareya. Shadreck M. Mareya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Benninga, Marc A., Sunny Z. Hussain, Manu R. Sood, et al.. (2021). Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension. Clinical Gastroenterology and Hepatology. 20(3). 602–610.e5. 31 indexed citations

Adams, Atoya, Charles F. Barish, Angel Chen, et al.. (2021). Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation. Advances in Therapy. 38(6). 2936–2952. 1 indexed citations

Hussain, Sunny Z., et al.. (2021). Safety of Lubiprostone in Pediatric Patients With Functional Constipation. Journal of Pediatric Gastroenterology and Nutrition. 73(5). 572–578. 7 indexed citations

Benninga, Marc A., et al.. (2018). Su1644 - Long-Term Open-Label Safety Extension Study Assessing Oral Lubiprostone in Children with Pediatric Functional Constipation Aged 6-17 Years. Gastroenterology. 154(6). S–560. 3 indexed citations

Webster, Lynn R., et al.. (2017). Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class. Pain Medicine. 19(6). 1195–1205. 13 indexed citations

Spierings, Egilius L.H., et al.. (2017). Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes. Pain Medicine. 19(6). 1184–1194. 11 indexed citations

Mareya, Shadreck M., et al.. (2016). Su1586 Lubiprostone Responder Rates in Patients With Chronic Idiopathic Constipation: Increased Frequencyoof Spontaneous Bowel Movements and Improved Constipation-Related Symptoms. Gastroenterology. 150(4). S534–S535. 1 indexed citations

Chang, Lin, et al.. (2016). Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. Alimentary Pharmacology & Therapeutics. 44(10). 1114–1122. 34 indexed citations

Spierings, Egilius L.H., et al.. (2016). Lubiprostone for Opioid‐Induced Constipation Does Not Interfere with Opioid Analgesia in Patients with Chronic Noncancer Pain. Pain Practice. 17(3). 312–319. 13 indexed citations

10.

Turner‐Bowker, Diane M., et al.. (2015). Development And Content Validity Of A Pediatric Functional Constipation Daily Diary. Value in Health. 18(3). A28–A28. 1 indexed citations

11.

Mareya, Shadreck M., et al.. (2015). Baseline Characteristics Associated With Response to Lubiprostone Treatment in Patients With Opioid-Induced Constipation. The American Journal of Gastroenterology. 110. S760–S761. 1 indexed citations

12.

Chang, Lin, et al.. (2015). Mo1262 Effects of Baseline Abdominal Pain on Response to Lubiprostone in Patients With Constipation-Predominant Irritable Bowel Syndrome. Gastroenterology. 148(4). S–653. 1 indexed citations

13.

Mareya, Shadreck M., et al.. (2013). Su2042 Time to Onset of Lubiprostone Treatment Effect in Chronic Non-Cancer Pain Patients With Opioid-Induced Constipation: Data From Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials. Gastroenterology. 144(5). S–540. 4 indexed citations

14.

Cryer, Byron, et al.. (2013). Spontaneous Bowel Movement Frequency Is Improved Over 12 Weeks of Lubiprostone Therapy in Opioid-induced Constipation Patients Regardless of Gender, Age, or Race: Pooled Analysis of Three Well-controlled Studies. The American Journal of Gastroenterology. 108. S567–S567. 1 indexed citations

15.

Jamal, M. Mazen, et al.. (2012). 848a Lubiprostone Significantly Improves Treatment Response in Non-Methadone Opioid-Induced Bowel Dysfunction Patients with Chronic, Non-Cancer Pain: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Gastroenterology. 142(5). S–144. 16 indexed citations

16.

Pimentel, Mark, Anthony Lembo, William D. Chey, et al.. (2011). Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. New England Journal of Medicine. 364(1). 22–32. 720 indexed citations breakdown →

17.

Chey, William D., Mark Pimentel, Dennis Riff, et al.. (2011). Time to Onset and Durability of Relief in Non-Constipation IBS Patients Over 12 Weeks Following a 2-Week Course of Rifaximin. Gastroenterology. 140(5). S–605. 2 indexed citations

18.

Pimentel, Mark, Anthony Lembo, William D. Chey, et al.. (2010). 475i Rifaximin Treatment for 2 Weeks Provides Acute and Sustained Relief Over 12 Weeks of IBS Symptoms in Non-Constipated Irritable Bowel Syndrome: Results From 2 North American Phase 3 Trials (Target 1 and Target 2). Gastroenterology. 138(5). S–64. 7 indexed citations

19.

Scherl, Ellen, Ronald E. Pruitt, Glenn L. Gordon, et al.. (2009). Safety and Efficacy of a New 3.3 g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. The American Journal of Gastroenterology. 104(6). 1452–1459. 41 indexed citations

20.

Rubin, David T., Alan Rosen, Shahriar Sedghi, et al.. (2008). T1147 Twice-Daily Balsalazide Tablets Improve Patient Quality of Life After 2 and 8 Weeks of Treatment: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Gastroenterology. 134(4). A–494.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact